Neurodegenerative diseases pose major challenges for societies with rapidly aging populations. Existing therapies are limited, and only treat the symptoms. Research employing animal models in the understanding of the pathologies and to develop new drugs, failed for now to discover and approve an efficient treatment for these diseases.
Therefore, JRC’s EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) launched a study to collect current and emerging non-animal models used in the field of neurodegenerative diseases. The overall aim of the current project is to provide an inventory and scientific evaluation of innovative (human-based) non-animal models/approaches currently in use for basic and applied research in the field of neurodegenerative diseases, more specifically Alzheimer’s and Parkinson’s disease.
The resulting inventory covers 567 methods, ranging from biochemical and computational approaches to different types of cell cultures or ex vivo human material. The inventory aims to contribute to the increased adoption and acceptance of alternative methods in neurodegeneration research and related fields. The work has been conducted within the context of a scientific collaboration between the JRC (Directorate for Health, Consumers and Reference Materials, Chemicals Safety and Alternative Methods Unit) and Imec, KU Leuven, VIB and VITO who received financial support through a JRC (contract ref: JRC/IPR/2017/F.3/0050/OC).
Build on reliable and scalable technology
FAQ
Frequently Asked Questions
Some basic informations about API Store ®.
Operation and development of APIs are currently fully funded by company Apitalks and its usage is for free.
Yes, you can.
All important information such as time of last update, license and other information are in response of each API call.
In case of major update that would not be compatible with previous version of API, we keep for 30 days both versions so you will have enough time to transfer to new version. We will inform you about the changes in advance by e-mail.